{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:27:04Z","timestamp":1791250024412,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":538,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cmi.2022.05.018","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T11:35:14Z","timestamp":1653737714000},"page":"1492-1498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV"],"prefix":"10.1016","volume":"28","author":[{"given":"Ana\u00efs","family":"Corma-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fern\u00e1ndez-Fuertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fuentes-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"G\u00f3mez-Ayerbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vi\u00f1uela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.05.018_bib1","doi-asserted-by":"crossref","first-page":"e2095","DOI":"10.1093\/cid\/ciaa1605","article-title":"Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): a prospective observational study","volume":"73","author":"Geretti","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.018_bib2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.05.018_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.05.018_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.05.018_bib5","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.cmi.2021.07.031","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1","volume":"27","author":"Levy","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.05.018_bib6","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/cid\/ciab648","article-title":"The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV)","volume":"74","author":"Woldemeskel","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.018_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/imr.12079","article-title":"HIV-associated chronic immune activation","volume":"254","author":"Paiardini","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1016\/j.cmi.2022.05.018_bib8","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cit937","article-title":"Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis","volume":"58","author":"Kern\u00e9is","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.018_bib9","author":"de Sanidad"},{"key":"10.1016\/j.cmi.2022.05.018_bib10","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1515\/cclm-2020-0594","article-title":"Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody","volume":"58","author":"Tr\u00e9-Hardy","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cmi.2022.05.018_bib11","series-title":"Roche Diagnostics GmbH. Elecsys anti-SARS-CoV-2 S assay","year":"2021"},{"key":"10.1016\/j.cmi.2022.05.018_bib12","doi-asserted-by":"crossref","unstructured":"Sun J, Patel RC, Zheng Q, Madhira V, Olex AL, Islam JY, et al. COVID-19 disease severity among people with HIV infection or solid organ transplant in the United States: a nationally-representative, multicenter, observational cohort study. medRxiv. In press. https:\/\/doi.org\/10.1101\/2021.07.26.21261028.","DOI":"10.1101\/2021.07.26.21261028"},{"key":"10.1016\/j.cmi.2022.05.018_bib13","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(21)00103-X","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial","volume":"8","author":"Frater","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2022.05.018_bib14","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1097\/QAD.0000000000002945","article-title":"Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV","volume":"35","author":"Ruddy","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2022.05.018_bib15","doi-asserted-by":"crossref","first-page":"103705","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cmi.2022.05.018_bib16","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1016\/j.vaccine.2022.04.090","article-title":"COVID-19 vaccine immunogenicity in people living with HIV-1","volume":"40","author":"Nault","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.05.018_bib17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/joim.13419","article-title":"Humoral response to two doses of BNT162b2 vaccination in people with HIV","volume":"291","author":"Heftdal","year":"2022","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.cmi.2022.05.018_bib18","unstructured":"Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A et\u00a0al. Immunogenicity of mRNA vaccination against SARS-CoV-2 in persons living with HIV (PLWHs) with low CD4 count or previous AIDS. Presented at: European AIDS Clinical Society 18th European AIDS Conference. London, UK; October 27\u201330, 2021."},{"key":"10.1016\/j.cmi.2022.05.018_bib19","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3018(21)00099-0","article-title":"Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV","volume":"8","author":"Touizer","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2022.05.018_bib20","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0000000000003166","article-title":"Impaired antibody response to COVID-19 vaccination in advanced HIV infection","volume":"36","author":"Hassold","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2022.05.018_bib21","doi-asserted-by":"crossref","first-page":"22777","DOI":"10.1038\/s41598-021-02321-z","article-title":"Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis","volume":"11","author":"Rotshild","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2022.05.018_bib22","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S2213-2600(21)00407-0","article-title":"Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?","volume":"9","author":"Milne","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2022.05.018_bib23","first-page":"291","article-title":"Durability of SARS-CoV-2 mRNA vaccine immune response in PLWH with advanced disease","volume":"2","author":"Cicalini","year":"2022","journal-title":"CROI"},{"key":"10.1016\/j.cmi.2022.05.018_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.cmi.2022.05.018_bib25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.cmi.2022.05.018_bib26","first-page":"291","article-title":"Immunogenicity and reactogenicity to CVOID-19 mRNA vaccine additional dose in PLWH","volume":"2","author":"Vergori","year":"2022","journal-title":"CROI"},{"key":"10.1016\/j.cmi.2022.05.018_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf3698","article-title":"Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection","volume":"5","author":"Reynolds","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.cmi.2022.05.018_bib28","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1038\/s41467-021-26137-7","article-title":"Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV","volume":"12","author":"Alrubayyi","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2022.05.018_bib29","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cmi.2021.06.023","article-title":"Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV research network cohort","volume":"27","author":"Berenguer","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.05.018_bib30","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cmi.2022.01.028","article-title":"Lower probability of persistence of total anti-SARS-CoV-2 antibodies after COVID-19 among people living with HIV","volume":"28","author":"Mac\u00edas","year":"2022","journal-title":"Clin Microbiol Infect"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22002762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22002762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:33:45Z","timestamp":1761118425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22002762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1198743X22002762"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.05.018","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}